Orvain C, Chantepie S, Thomas X, Escofrre-Barbe M, Huguet F, Desbrosses Y, et al. Impact of central nervous system involvement in adult patients with Philadelphia-negative acute lymphoblastic leukemia: a GRAALL-2005 study. Haematologica. 2023. https://doi.org/10.3324/haematol.2022.282332.
Google ScholarÂ
Kantarjian HM, Walters RS, Smith TL, Keating MJ, Barlogie B, McCredie KB, et al. Identification of risk groups for development of central nervous system leukemia in adults with acute lymphocytic leukemia. Blood. 1988;72:1784–9.
Google ScholarÂ
Surapaneni UR, Cortes JE, Thomas D, O’Brien S, Giles FJ, Koller C, et al. Central nervous system relapse in adults with acute lymphoblastic leukemia. Cancer. 2002;94:773–9.
Google ScholarÂ
Kopmar NE, Cassaday RD. How I prevent and treat central nervous system disease in adults with acute lymphoblastic leukemia. Blood. 2023;141:1379–88. https://doi.org/10.1182/blood.2022017035.
Google ScholarÂ
Hamdi A, Mawad R, Bassett R, di Stasi A, Ferro R, Afrough A, et al. Central nervous system relapse in adults with acute lymphoblastic leukemia after allogeneic hematopoietic stem cell transplantation. Biol Blood Marrow Transpl. 2014;20:1767–71. https://doi.org/10.1016/j.bbmt.2014.07.005.
Google ScholarÂ
Oshima K, Kanda Y, Yamashita T, Takahashi S, Mori T, Nakaseko C, et al. Central nervous system relapse of leukemia after allogeneic hematopoietic stem cell transplantation. Biol Blood Marrow Transpl. 2008;14:1100–7. https://doi.org/10.1016/j.bbmt.2008.07.002.
Google ScholarÂ
Lee S, Kim DW, Cho BS, Yoon JH, Shin SH, Yahng SA, et al. Impact of minimal residual disease kinetics during imatinib-based treatment on transplantation outcome in Philadelphia chromosome-positive acute lymphoblastic leukemia. Leukemia. 2012;26:2367–74. https://doi.org/10.1038/leu.2012.164.
Google ScholarÂ
Yoon J-H, Min GJ, Park S-S, Jeon Y-W, Lee S-E, Cho B-S, et al. Minimal residual disease–based long-term efficacy of reduced-intensity conditioning versus myeloablative conditioning for adult Philadelphia-positive acute lymphoblastic leukemia. Cancer. 2019;125:873–83. https://doi.org/10.1002/cncr.31874.
Google ScholarÂ
Yoon JH, Min GJ, Park SS, Park S, Lee SE, Cho BS, et al. Impact of donor type on long-term graft-versus-host disease-free/relapse-free survival for adult acute lymphoblastic leukemia in first remission. Bone Marrow Transpl. 2021;56:828–40. https://doi.org/10.1038/s41409-020-01097-6.
Google ScholarÂ
Yoon JH, Min GJ, Park SS, Park S, Lee SE, Cho BS, et al. Durable outcomes of double cord blood transplantation in adults with acute lymphoblastic leukemia: high-risk features for early and long-term mortality. Ther Adv Hematol. 2022;13:20406207221076762. https://doi.org/10.1177/20406207221076762.
Google ScholarÂ
Yoon J-H, Min GJ, Park S-S, Park S, Lee S-E, Cho B-S, et al. Impact of donor type on long-term graft-versus-host disease-free/relapse-free survival for adult acute lymphoblastic leukemia in first remission. Bone Marrow Transpl. 2021;56:828–40. https://doi.org/10.1038/s41409-020-01097-6.
Google ScholarÂ
Kanda Y. Investigation of the freely available easy-to-use software ‘EZR’ for medical statistics. Bone Marrow Transpl. 2013;48:452–8. https://doi.org/10.1038/bmt.2012.244.
Google ScholarÂ
Harker-Murray PD, Thomas AJ, Wagner JE, Weisdorf D, Luo X, DeFor TE, et al. Allogeneic hematopoietic cell transplantation in children with relapsed acute lymphoblastic leukemia isolated to the central nervous system. Biol Blood Marrow Transpl. 2008;14:685–92. https://doi.org/10.1016/j.bbmt.2008.03.011.
Google ScholarÂ
Blum S, Chalandon Y, Labopin M, Finke J, Gedde-Dahl T, Othman TB, et al. Incidence and outcome of central nervous system relapse after hematopoietic stem cell transplantation in patients suffering from acute myeloid leukemia and acute lymphoblastic leukemia: a study from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation. Haematologica. 2024;109:2346–50. https://doi.org/10.3324/haematol.2023.284858.
Google ScholarÂ
Lazarus HM, Richards SM, Chopra R, Litzow MR, Burnett AK, Wiernik PH, et al. Central nervous system involvement in adult acute lymphoblastic leukemia at diagnosis: results from the international ALL trial MRC UKALL XII/ECOG E2993. Blood. 2006;108:465–72. https://doi.org/10.1182/blood-2005-11-4666.
Google ScholarÂ
Kantarjian H, Short NJ, Haddad FG, Jain N, Huang X, Montalban-Bravo G, et al. Results of the Simultaneous Combination of Ponatinib and Blinatumomab in Philadelphia Chromosome-Positive ALL. J Clin Oncol. 2024;42:4246–51. https://doi.org/10.1200/JCO.24.00272.
Google ScholarÂ
Short NJ, Kantarjian H, Furudate K, Jain N, Ravandi F, Karrar O, et al. Molecular characterization and predictors of relapse in patients with Ph + ALL after frontline ponatinib and blinatumomab. J Hematol Oncol. 2025;18:55 https://doi.org/10.1186/s13045-025-01709-y.
Google ScholarÂ
Yao H, Price TT, Cantelli G, Ngo B, Warner MJ, Olivere L, et al. Leukaemia hijacks a neural mechanism to invade the central nervous system. Nature. 2018;560:55–60. https://doi.org/10.1038/s41586-018-0342-5.
Google ScholarÂ
Cho BS, Min GJ, Park SS, Yoon SY, Park S, Jeon YW, et al. Low-dose thymoglobulin for prevention of chronic graft-versus-host disease in transplantation from an HLA-matched sibling donor. Am J Hematol. 2021;96:1441–9. https://doi.org/10.1002/ajh.26320.
Google ScholarÂ
Giebel S, Labopin M, Czerw T, Socié G, Blaise D, Ghavamzadeh A, et al. Impact of anti-thymocyte globulin on results of allogeneic peripheral blood stem cell transplantation for patients with Philadelphia-positive acute lymphoblastic leukaemia: An analysis by the Acute Leukemia Working Party of the EBMT. Eur J Cancer. 2019;106:212–9. https://doi.org/10.1016/j.ejca.2018.11.003.
Google ScholarÂ
Wakamatsu M, Terakura S, Ohashi K, Fukuda T, Ozawa Y, Kanamori H, et al. Impacts of thymoglobulin in patients with acute leukemia in remission undergoing allogeneic HSCT from different donors. Blood Adv. 2019;3:105–15. https://doi.org/10.1182/bloodadvances.2018025643.
Google ScholarÂ
Yuan F, Li G, Li M, Wei X, Fu Y. Haploidentical Cord Blood Transplantation with 8 mg/kg Antithymocyte Globulin as Graft-versus-Host Disease Prophylaxis Compared to Haploidentical Transplantation with 10 mg/kg Antithymocyte Globulin in the Treatment of Acute Leukemia. Transpl Cell Ther. 2023;29:771.e771–771.e710. https://doi.org/10.1016/j.jtct.2023.09.015.
Google ScholarÂ
Del Principe MI, Buzzatti E, Piciocchi A, Forghieri F, Bonifacio M, Lessi F, et al. Clinical significance of occult central nervous system disease in adult acute lymphoblastic leukemia. A multicenter report from the Campus ALL Network. Haematologica. 2021;106:39–45. https://doi.org/10.3324/haematol.2019.231704.
Google ScholarÂ
Cordova-Serrano RD, Almanza-Huante E, Fernandez-Sanchez E, Hernandez-Alcantara A, Espinosa-Bautista K. Central nervous system (CNS) involvement has an adverse impact on survival in newly diagnosed adult acute lymphoblastic leukemia (ALL) assessed by flow cytometry. Leuk Lymphoma. 2021;62:3264–70. https://doi.org/10.1080/10428194.2021.1957872.
Google ScholarÂ
Dargenio M, Bonifacio M, Chiaretti S, Vitale A, Fracchiolla NS, Papayannidis C, et al. Incidence, treatment and outcome of central nervous system relapse in adult acute lymphoblastic leukaemia patients treated front-line with paediatric-inspired regimens: A retrospective multicentre Campus ALL study. Br J Haematol. 2023;200:440–50. https://doi.org/10.1111/bjh.18537.
Google ScholarÂ
Martinez-Laperche C, Gomez-Garcia AM, Lassaletta A, Moscardo C, Vivanco JL, Molina J, et al. Detection of occult cerebrospinal fluid involvement during maintenance therapy identifies a group of children with acute lymphoblastic leukemia at high risk for relapse. Am J Hematol. 2013;88:359–64. https://doi.org/10.1002/ajh.23407.
Google ScholarÂ
Paul S, Kantarjian H, Sasaki K, Marx K, Jain N, Savoy JM, et al. Intrathecal prophylaxis with 12 versus 8 administrations reduces the incidence of central nervous system relapse in patients with newly diagnosed Philadelphia chromosome positive acute lymphoblastic leukemia. Am J Hematol. 2023;98:E11–E14. https://doi.org/10.1002/ajh.26622.
Google ScholarÂ
Zhu Y, Zhu Y, Miao L, Jia T, Mao J, Xue L, et al. Comparison of the Efficacy and Safety of Ponatinib and Dasatinib in Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia With Central Nervous System Relapse: A Retrospective Study. Technol Cancer Res Treat. 2023;22:15330338231165866. https://doi.org/10.1177/15330338231165866.
Google ScholarÂ
Chiaretti S, Leoncin M, Elia L, Piciocchi A, Matarazzo M, Di Trani M, et al. Comparison between Dasatinib-Blinatumomab Vs Ponatinib-Blinatumomab Chemo-Free Strategy for Newly Diagnosed Ph+ Acute Lymphoblastic Leukemia Patients. Preliminary Results of the Gimema ALLL2820 Trial. Blood. 2023;142:4249–4249. https://doi.org/10.1182/blood-2023-189632.
Google ScholarÂ
Porkka K, Koskenvesa P, Lundan T, Rimpilainen J, Mustjoki S, Smykla R, et al. Dasatinib crosses the blood-brain barrier and is an efficient therapy for central nervous system Philadelphia chromosome-positive leukemia. Blood. 2008;112:1005–12. https://doi.org/10.1182/blood-2008-02-140665.
Google ScholarÂ
Ravi K, Franson A, Homan MJ, Roberts H, Pai MP, Miklja Z, et al. Comparative pharmacokinetic analysis of the blood-brain barrier penetration of dasatinib and ponatinib in mice. Leuk Lymphoma. 2021;62:1990–4. https://doi.org/10.1080/10428194.2021.1894647.
Google ScholarÂ
Foa R, Bassan R, Elia L, Piciocchi A, Soddu S, Messina M, et al. Long-Term Results of the Dasatinib-Blinatumomab Protocol for Adult Philadelphia-Positive ALL. J Clin Oncol. 2024;42:881–5. https://doi.org/10.1200/JCO.23.01075.
Google ScholarÂ
